Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.65 |
| ▸ | NT5E | P21589 | 4/20 | 0.64 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839755 | 0.91 | DNPH1 (0.64) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL30395306 | 0.89 | DNPH1 (0.81) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL21839611 | 0.89 | DNPH1 (0.81) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL23915551 | 0.88 | NT5E (0.52) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL21839764 | 0.88 | DNPH1 (0.70) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL21839620 | 0.85 | ADORA3 (0.65) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL21839668 | 0.84 | DNPH1 (0.69) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL21839800 | 0.84 | ADORA3 (0.73) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL30394844 | 0.84 | ADORA3 (0.73) | DNPH1NT5EP2RX3P2RX2SLC29A1 | |
| SCHEMBL21839573 | 0.83 | NT5E (0.63) | DNPH1NT5EP2RX3P2RX2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | DNPH1 297/4885NT5E 3/4885P2RX3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.